Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 19, 2026

Collegium Pharmaceutical: Buying The Projected Growth For 2026

Collegium Pharmaceutical demonstrates strong profitability, upgraded 2026 guidance, and a robust balance sheet, reinforcing my bullish outlook and conviction upgrade. COLL's growth is shifting from Xtampza ER to Jornay PM, which is expected to drive $190M–$200M in 2025 revenue and deeper ADHD market penetration. The pain portfolio remains a stable cash generator, with authorized generics providing a smart revenue stream and mitigating immediate generic erosion risks.

Seeking Alpha • Jan 22, 2026

Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference

STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older and developed using a novel delayed-release extended-release delivery platform, at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Conference being held from January 15-18, 2026, in San Diego, California.

GlobeNewsWire • Jan 15, 2026

Collegium Pharmaceutical EVP Sells COLL 17,600 Shares Amid Strong Close of 2025

On Dec. 8, 2025, the Executive Vice President and Chief Commercial Officer of Collegium Pharmaceutical sold 17,600 shares directly through an exercise of options. The sale represented 14.5% of Dreyer's direct holdings at the time, reducing his direct ownership to 103,613 shares.

The Motley Fool • Jan 14, 2026

Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Jan 12, 2026

Collegium Provides 2026 Financial Guidance and Business Update

– Product Revenues, Net Expected in the Range of $805 Million to $825 Million – – Jornay PM ® Net Revenue Expected in the Range of $190 Million to $200 Million – – Adjusted EBITDA* Expected in the Range of $455 Million to $475 Million – STOUGHTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced its 2026 full-year financial guidance and provided a business update.

GlobeNewsWire • Jan 8, 2026

Collegium Announces the Closing of $980 Million Syndicated Credit Facility

STOUGHTON, Mass., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), today announced the closing of its inaugural syndicated credit facility.

GlobeNewsWire • Dec 30, 2025

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Dec 22, 2025

Best Value Stocks to Buy for Dec. 18

KE, COLL and JRVR made it to the Zacks Rank #1 (Strong Buy) value stocks list on Dec. 18, 2025.

Zacks Investment Research • Dec 18, 2025

Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run?

Collegium Pharmaceutical (COLL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Investment Research • Dec 4, 2025